Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Abstract 


Men are more likely than women to die due to coronavirus disease 2019 (COVID-19). This paper sets out to examine whether the magnitude of the sex differences in the COVID-19 mortality rate are unusual when compared to other common causes of death. In doing so, we aim to provide evidence as to whether the causal pathways for the sex differences in the mortality rate of COVID-19 likely differ from those for other causes of death. We found that sex differences in the age-standardized COVID-19 mortality rate were substantially larger than for the age-standardized all-cause mortality rate and most other common causes of death. These differences were especially large in the oldest age groups.

One Sentence Summary

The sex difference in the mortality rate of coronavirus disease 2019 is substantially larger than for other common causes of death.

Free full text 


medRxiv

PPRID: PPR289354
EMSID: EMS117713
medRxiv preprint, version 1, posted 2021 February 26
https://doi.org/10.1101/2021.02.23.21252314

Sex differences in the mortality rate for coronavirus disease 2019 compared to other causes of death

Affiliations

  1. 1. Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, California, USA.
  2. 2. Heidelberg Institute of Global Health, Heidelberg University, Heidelberg, Germany.
  3. 3. Division of Preventive Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  4. 4. Department of Disease Control and Environmental Health, School of Public Health, College of Health Sciences, Makerere University, Kampala, Uganda.
  5. 5. Stanford University School of Medicine, Stanford, California, USA.
  6. 6. Laboratory of Population Health, Max Planck Institute for Demographic Research, Rostock, Germany.
  7. 7. Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.

Copyright and license information

Copyright notice

This preprint is made available via the Europe PMC open access subset, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.

This article is a preprint. A journal published article is available.

Abstract

Men are more likely than women to die due to coronavirus disease 2019 (COVID-19). This paper sets out to examine whether the magnitude of the sex differences in the COVID-19 mortality rate are unusual when compared to other common causes of death. In doing so, we aim to provide evidence as to whether the causal pathways for the sex differences in the mortality rate of COVID-19 likely differ from those for other causes of death. We found that sex differences in the age-standardized COVID-19 mortality rate were substantially larger than for the age-standardized all-cause mortality rate and most other common causes of death. These differences were especially large in the oldest age groups.

Introduction

Males have a higher risk of death from coronavirus disease 2019 (COVID-19) than females 16 . This difference has been observed for both the case fatality rate (CFR; i.e., deaths among those diagnosed with a SARS-CoV-2 infection) and infection fatality rate (IFR; i.e., deaths among all those who were infected with SARS-CoV-2) 1 . This higher risk of death from COVID-19 in males has been highlighted both in the academic literature and the media 79 .

Understanding why these disparities by sex exist has become an active area of research. However, given that the risk of death from COVID-19 is strongly related to one’s expected remaining life expectancy 6 , it is unclear whether the observed sex differences in the COVID-19 fatality rate are simply a reflection of men’s shorter life expectancy 10 , which is at least in part due to their poorer health status at any given age. This study aimed to determine if sex differences in COVID-19 mortality are larger when compared to the all-cause mortality rate, mortality rates for other common causes of death, and – given SARS-CoV-2’s common respiratory manifestations – other respiratory causes of death, including respiratory infections. This information is crucial, as it begins to elucidate whether the higher COVID-19 mortality risk among males reflects the survival advantage among females compared to males, and is, thus, likely a result of the biological, behavioral, and social pathways that cause this survival advantage as opposed to causal pathways that are specific to COVID-19. Understanding these causal pathways could help in the development of therapeutics and preventive measures for COVID-19 and future coronavirus disease outbreaks.

Results

We extracted the latest available country-level data on COVID-19 deaths from the COVerAGE-DB for countries for which age- and sex-disaggregated data were available (as of 09 February 2021) 11 . We then obtained age- and sex-disaggregated data on all-cause mortality and population size for each of these countries from the Human Mortality Database (HMD) 12 and, for countries not included in the HMD, from the United Nation’s World Population Prospects (WPP) 10 . The latest available mortality data for specific causes of death were drawn from the World Health Organization’s (WHO) mortality database 13 . We then calculated the ratios for the sex difference in the COVID-19 mortality (i.e., the ratio of the number of COVID-19 deaths in men divided by the male mid-year population to the number of COVID-19 deaths in women divided by the female mid-year population) and compared these ratios to those for i) all-cause mortality, ii) each of the six most common causes of death groups globally for adults (excluding injuries) 14 , and iii) each major respiratory cause of death.

Age- and sex-disaggregated data on COVID-19 deaths were available for 59 countries (Table 1).

Table 1. Population, all-cause deaths, and COVID-19 cases and deaths by sex and country
All-cause mortality COVID-19 mortality
Population (000s) Deaths (000s) Deaths
Country Period/year Female Male Female Male Date* Female Male
Afghanistan 2015-2020 18,952 19,976 549 646 28.11.2020 381 1,130
Argentina 2015-2020 23,147 22,049 802 878 15.01.2021 19,648 26,539
Australia 2018 12,495 12,298 76 82 07.02.2021 468 441
Belgium 2018 5,794 5,630 57 54 07.02.2021 10,880 10,479
Brazil 2015-2020 108,124 104,436 2,901 3,790 01.02.2021 84,023 111,936
Canada 2018 18,513 18,249 139 144 22.09.2020 4,516 4,672
Chad 2015-2020 8,226 8,200 445 490 21.10.2020 27 65
Chile 2017 8,923 8,573 51 56 13.01.2021 7,449 9,986
Colombia 2015-2020 25,898 24,985 617 742 07.02.2021 22,852 40,064
Croatia 2018 2,124 1,982 27 26 20.12.2020 345 332
Cuba 2015-2020 5,703 5,623 239 266 24.05.2020 33 49
Cyprus 2015-2020 604 604 20 22 29.11.2020 40 103
Czechia 2018 5,390 5,220 56 57 07.02.2021 7,167 9,327
Denmark 2019 2,917 2,889 27 27 02.02.2021 995 1,165
Ecuador 2015-2020 8,819 8,824 188 243 31.07.2020 3,590 7,025
Estonia 2019 699 626 8 7 13.12.2020 131 97
Eswatini 2015-2020 590 570 24 29 30.12.2020 78 106
Finland 2019 2,795 2,723 27 27 20.12.2020 270 402
France 2018 33,419 31,324 300 297 28.01.2021 22,052 30,657
Germany 2017 41,824 40,697 475 458 07.02.2021 29,827 31,839
Greece 2017 5,549 5,222 61 63 16.01.2021 2,241 3,199
Hungary 2017 5,122 4,675 68 64 29.11.2020 296 293
Iceland 2018 171 178 1 1 29.11.2020 45 60
India 2015-2020 662,903 717,101 22,515 26,158 02.10.2020 30,987 69,888
Iraq 2015-2020 19,865 20,358 417 492 24.05.2020 50 110
Ireland 2017 2,413 2,365 15 15 20.12.2020 971 1,029
Israel 2016 4,268 4,195 22 22 09.12.2020 1,260 1,672
Italy 2017 31,121 29,404 340 311 05.01.2021 32,481 42,567
Japan 2019 63,705 60,392 674 707 18.08.2020 294 531
Jordan 2015-2020 5,037 5,166 84 104 07.02.2021 1,557 2,822
Kenya 2015-2020 27,053 26,719 641 761 11.10.2020 72 208
Latvia 2017 1,054 896 15 14 29.11.2020 49 40
Lithuania 2019 1,499 1,296 20 18 29.11.2020 120 171
Luxembourg 2019 305 309 2 2 20.12.2020 162 178
Malawi 2015-2020 9,696 9,434 274 333 27.12.2020 45 143
Malta 2015-2020 220 221 9 9 20.12.2020 84 243
Mexico 2015-2020 65,861 63,071 1,688 2,058 13.01.2021 50,228 86,689
Nepal 2015-2020 15,788 13,348 437 460 26.09.2020 101 259
Netherlands 2018 8,654 8,527 79 75 14.02.2021 6,595 7,808
Nigeria 2015-2020 101,670 104,470 5,546 6,038 17.01.2021 306 840
Pakistan 2015-2020 107,220 113,672 3,364 3,974 02.06.2020 435 1,253
Panama 2015-2020 2,155 2,160 44 61 04.07.2020 219 501
Paraguay 2015-2020 3,508 3,624 85 104 16.01.2021 912 1,408
Peru 2015-2020 16,593 16,379 374 491 04.02.2021 13,506 28,432
Philippines 2015-2020 54,552 55,029 1,249 1,836 04.02.2021 4,404 6,713
Poland 2018 19,840 18,593 201 214 20.12.2020 1,385 2,057
Portugal 2018 5,425 4,869 56 57 02.02.2021 6,367 6,890
Romania 2015-2020 9,884 9,354 621 654 29.11.2020 362 490
Slovakia 2017 2,784 2,652 26 27 20.12.2020 964 1,047
Slovenia 2017 1,041 1,025 10 10 31.01.2021 1,964 1,795
South Korea 2018 25,680 25,595 138 161 28.06.2020 134 148
Spain 2018 23,776 22,881 210 215 04.02.2021 27,559 33,065
Switzerland 2018 4,278 4,206 35 32 08.02.2021 4,121 4,747
Togo 2015-2020 4,159 4,119 164 170 02.02.2021 18 59
Turkey 2015-2020 42,703 41,636 997 1,201 26.10.2020 3,541 6,258
Ukraine 2013 24,407 20,961 338 325 06.02.2021 7,568 9,827
United Kingdom 2018 33,554 32,687 312 304 01.01.2021 40,282 48,960
Uruguay 2015-2020 1,795 1,678 81 82 18.01.2021 74 236
USA 2018 165,365 160,460 1,381 1,458 26.12.2020 192,335 228,829

Year for which population and deaths data are available in the HMD. Population and mortality projections for the 2015-2020 period from the UN’s World Population Prospects (WPP) were used for countries not in the HMD.

* Date when latest sex-disaggregated data were available for each country.

Caption: We extracted latest available population and deaths count data for each country. Population and deaths count data were available for 32 countries from the Human Mortality Database (HMD): Australia, Belgium, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Luxembourg, Netherlands, Poland, Portugal, Slovakia, Slovenia, South Korea, Spain, Switzerland, Ukraine, United Kingdom and USA. For countries not in the HMD, we obtained the standard projections of population numbers and deaths for the 2015-2020 period from the United Nation’s World Population Prospects (WPP) (https://population.un.org/wpp/Download/Standard/Population/).

From this data, we calculated the age-standardized male-to-female rate ratios of mortality from COVID-19 and all-causes. The age standardization, conducted separately for each country, was carried out to ensure that differences in the male-to-female mortality rate ratio between COVID-19 and all causes were not confounded by sex differences in the age distribution. Point estimates greater than one in Figure 1 indicate that men had a higher rate of death than women. We found that in most countries, the male disadvantage for COVID-19 mortality was substantially larger than their all-cause mortality disadvantage (Figure 1 and Figure S1).

Figure 1
Open in new tabFigure 1: Male-to-female rate ratios of mortality from COVID-19 and all causes.

Caption: Rate ratios for the sex differences in COVID-19 and all-cause mortality were calculated for each country by dividing the age-standardized mortality rate in males by the age-standardized mortality rate in females.

Next, we investigated whether the degree of the male disadvantage in the COVID-19 compared to the all-cause mortality varied by age group. To do so, we divided – separately by ten-year age group – the age-standardized male-to-female rate ratio for the COVID-19 mortality by the age-standardized male-to-female rate ratio for all-cause mortality. Point estimates greater than one in Figure 2, thus, indicate that the sex differences in the mortality rate for COVID-19 were greater than expected based on the sex differences in the all-cause mortality rate. We found that among the older age groups, especially the group aged 80 years and older, the higher rate of death for men than woman exceeded (in relative terms) that for all-cause mortality for most countries. Among younger age groups, especially those aged less than 50 years, the direction and magnitude of these differences varied greatly by country. These patterns are similar when adjusting these estimates for remaining life expectancy (Figure S2).

Figure 2
Open in new tabFigure 2: Relative difference in the male-to-female rate ratios of COVID-19-specific and all-cause mortality, by age group.

Caption: The relative difference in the rate ratio was calculated by dividing (separately among each age group shown) the male-to-female rate ratio for the COVID-19-specific mortality rate by the male-to-female rate ratio for the all-cause mortality rate.

Using the same metric as for Figure 2, we then compared the relative magnitude of sex differences in the mortality for COVID-19 to that for other major causes of mortality (circulatory diseases, cancer, chronic respiratory diseases, respiratory infections and tuberculosis, diabetes, and neurologic disorders). We found that in most countries the relative sex differences for COVID-19 were larger than for each of the other common causes of death (Figure 3 and Figure S3). However, this was not true for chronic respiratory conditions for which countries were spread approximately equally across the vertical dashed line drawn at one (i.e., the number indicating that the relative sex difference for the COVID-19 mortality was the same as for chronic respiratory diseases). Implementing the same analysis as in Figure 3 for each common respiratory cause of death (the ICD-10 codes used for categorization are shown in Table S2) revealed that the similar male disadvantage in mortality for chronic respiratory diseases as for COVID-19 is largely driven by a high male disadvantage in mortality from bronchitis and emphysema (Figure S4) and, thus, likely the higher prevalence of smoking (especially in the past) among men than women 15,16 .

Figure 3
Open in new tabFigure 3: Relative difference in the male-to-female rate ratios of COVID-19-specific mortality and six major causes of mortality

Discussion

The degree to which men are more likely to die from COVID-19 than women is substantially larger than would be expected merely based on the fact that men are generally more likely to die at any given age than women. Thus, the probability of succumbing to a SARS-CoV-2 infection does not appear to be fully explained by the remaining life expectancy of the person who was infected. This observation suggests that the causal pathways that link male sex to a shorter life expectancy may not fully explain the unusually high male disadvantage in COVID-19 mortality. Our findings, therefore, lend support to hypotheses that posit that the causal pathways that link male sex to a higher mortality from a SARS-CoV-2 infection are specific to SARS-CoV-2 rather than shared with the pathways responsible for the shorter life expectancy among men than women or the causal pathways for sex differences for other common causes of death.

This study has several limitations. First and foremost, this study can only provide suggestive (as opposed to conclusive) evidence as to whether or not the causal pathways underlying the male disadvantage for COVID-19 mortality are shared with those underlying the all-cause mortality disadvantage for men. Second, our mortality rate calculations for COVID-19 use the total population (by sex) as the denominator. Thus, the assumption underlying the validity of our calculation is that there are no substantial differences in the probability of being infected with SARS-CoV-2 between males and females. To date, evidence from seroprevalence studies suggests that this assumption is reasonable 17,18 . An alternative approach is to use the number of identified cases of SARS-CoV-2 infections as the denominator (i.e., calculating the case fatality rate). This approach, however, assumes that the degree of underdetection of SARS-CoV-2 infections is the same among men as among women. This assumption would, for example, be violated if males are more likely to develop symptoms from a SARS-CoV-2 infection than females and are, therefore, more likely to seek out a COVID-19 test, or if men have better access to testing than women. Although both choices for the denominator (total population or number of cases) rely on untestable assumptions, our analyses in which we use the number of cases instead of the total population as denominator found that the choice of denominator does not substantially change our conclusions.

Studies have hypothesized that the sex differences in COVID-19 mortality exist due to behavioral and social risk factors (e.g., higher incidence of smoking and drinking among men than women) that place men at a greater risk of mortality from health complications associated with COVID-19 1924 . Other studies have cited a higher rate of comorbidities, such as diabetes and heart disease, as the reason for the higher COVID-19 fatality rate among men 4,2528 . Finally, some studies suggest biological factors that may explain these disparities. One potential factor is a higher expression among men than women of the angiotensin-converting enzyme 2 receptor, which is used by SARS-CoV-2 to enter the host cell 3,29,30 . Other possible biological factors relate to immunological differences between males and females 3133 . Ultimately a combination of biological, behavioral, and social pathways may be responsible for the high male disadvantage in COVID-19 mortality. Elucidating these causal chains is an important research area given that it may assist in the development of therapeutics and preventive measures for COVID-19 and future outbreaks of coronavirus diseases.

One Sentence Summary

The sex difference in the mortality rate of coronavirus disease 2019 is substantially larger than for other common causes of death.

Supplementary Material

Funding

PG was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number KL2TR003143

Author Information

Correspondence to: Pascal Geldsetzer, Division of Primary Care and Population Health, Department of Medicine, Stanford University, 1265 Welch Road, Stanford, California 94305, USA, ude.drofnats@reztesdlegp

Author contributions: Pascal Geldsetzer: conceptualization, methodology, writing – original draft preparation; Trasias Mukama: methodology, data analysis, writing – reviewing and editing; Nadine Jawad: methodology, writing – original draft preparation; Tim Riffe: conceptualization, methodology, writing – reviewing and editing; Angela Rogers: methodology, writing – reviewing and editing; Nikkil Sudharsanan: conceptualization, methodology, writing – reviewing and editing;

Competing interests: The authors declare no competing interests;

Data and materials availability

All the data used in the study are publicly available. COVID-19 mortality data are available from the COVerAGE-DB (https://osf.io/mpwjq/). Data on population size by age and sex are available from the HMD (www.mortality.org) and the United Nation’s WPP (https://www.who.int/healthinfo/mortality_data/en/).

References

History

  • Posted February 26, 2021.